Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer

Yoichi Nakanishi, Masayuki Kawasaki, Fen Bai, Koichi Takayama, Xin Hai Pei, Koichi Takano, Koji Inoue, Sin Ichi Osaki, Nobuyuki Hara, Chikako Kiyohara

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

To determine the predictive value of the expression of p53 and glutathione S-transferase-π (GST-π) with respect to chemotherapy response, immunostaining was performed on transbronchial biopsy specimens from previously untreated patients with non-small cell lung cancer. Of the 54 patients, 34 patients (63%) and 37 patients (69%) were positive for p53 and GST-π, respectively. The response rates in the p53-positive and p53-negative group were 15 and 45%, and those in GST-π-positive and GST-π-negative groups were 16 and 47%, respectively. A multiple logistic regression analysis revealed that positive immunostaining for GST-π was a significant risk factor for clinical chemotherapy resistance. The combination of these two markers was the most important independent factor in predicting a response to chemotherapy in multiple logistic regression analysis. Immunohistochemical expression of p53 and GST-π was independently related to clinical chemoresistance in patients with non-small cell lung cancer. Combined use of these two biomarkers may be a useful predictor of clinical chemoresistance.

Original languageEnglish
Pages (from-to)318-323
Number of pages6
JournalOncology
Volume57
Issue number4
DOIs
Publication statusPublished - Jan 1 1999

Fingerprint

Glutathione Transferase
Drug Resistance
Non-Small Cell Lung Carcinoma
Drug Therapy
Logistic Models
Regression Analysis
Biomarkers
Biopsy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer. / Nakanishi, Yoichi; Kawasaki, Masayuki; Bai, Fen; Takayama, Koichi; Pei, Xin Hai; Takano, Koichi; Inoue, Koji; Osaki, Sin Ichi; Hara, Nobuyuki; Kiyohara, Chikako.

In: Oncology, Vol. 57, No. 4, 01.01.1999, p. 318-323.

Research output: Contribution to journalArticle

Nakanishi, Y, Kawasaki, M, Bai, F, Takayama, K, Pei, XH, Takano, K, Inoue, K, Osaki, SI, Hara, N & Kiyohara, C 1999, 'Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer', Oncology, vol. 57, no. 4, pp. 318-323. https://doi.org/10.1159/000012068
Nakanishi, Yoichi ; Kawasaki, Masayuki ; Bai, Fen ; Takayama, Koichi ; Pei, Xin Hai ; Takano, Koichi ; Inoue, Koji ; Osaki, Sin Ichi ; Hara, Nobuyuki ; Kiyohara, Chikako. / Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer. In: Oncology. 1999 ; Vol. 57, No. 4. pp. 318-323.
@article{fcd157394a904d75a55b665f021ec40d,
title = "Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer",
abstract = "To determine the predictive value of the expression of p53 and glutathione S-transferase-π (GST-π) with respect to chemotherapy response, immunostaining was performed on transbronchial biopsy specimens from previously untreated patients with non-small cell lung cancer. Of the 54 patients, 34 patients (63{\%}) and 37 patients (69{\%}) were positive for p53 and GST-π, respectively. The response rates in the p53-positive and p53-negative group were 15 and 45{\%}, and those in GST-π-positive and GST-π-negative groups were 16 and 47{\%}, respectively. A multiple logistic regression analysis revealed that positive immunostaining for GST-π was a significant risk factor for clinical chemotherapy resistance. The combination of these two markers was the most important independent factor in predicting a response to chemotherapy in multiple logistic regression analysis. Immunohistochemical expression of p53 and GST-π was independently related to clinical chemoresistance in patients with non-small cell lung cancer. Combined use of these two biomarkers may be a useful predictor of clinical chemoresistance.",
author = "Yoichi Nakanishi and Masayuki Kawasaki and Fen Bai and Koichi Takayama and Pei, {Xin Hai} and Koichi Takano and Koji Inoue and Osaki, {Sin Ichi} and Nobuyuki Hara and Chikako Kiyohara",
year = "1999",
month = "1",
day = "1",
doi = "10.1159/000012068",
language = "English",
volume = "57",
pages = "318--323",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer

AU - Nakanishi, Yoichi

AU - Kawasaki, Masayuki

AU - Bai, Fen

AU - Takayama, Koichi

AU - Pei, Xin Hai

AU - Takano, Koichi

AU - Inoue, Koji

AU - Osaki, Sin Ichi

AU - Hara, Nobuyuki

AU - Kiyohara, Chikako

PY - 1999/1/1

Y1 - 1999/1/1

N2 - To determine the predictive value of the expression of p53 and glutathione S-transferase-π (GST-π) with respect to chemotherapy response, immunostaining was performed on transbronchial biopsy specimens from previously untreated patients with non-small cell lung cancer. Of the 54 patients, 34 patients (63%) and 37 patients (69%) were positive for p53 and GST-π, respectively. The response rates in the p53-positive and p53-negative group were 15 and 45%, and those in GST-π-positive and GST-π-negative groups were 16 and 47%, respectively. A multiple logistic regression analysis revealed that positive immunostaining for GST-π was a significant risk factor for clinical chemotherapy resistance. The combination of these two markers was the most important independent factor in predicting a response to chemotherapy in multiple logistic regression analysis. Immunohistochemical expression of p53 and GST-π was independently related to clinical chemoresistance in patients with non-small cell lung cancer. Combined use of these two biomarkers may be a useful predictor of clinical chemoresistance.

AB - To determine the predictive value of the expression of p53 and glutathione S-transferase-π (GST-π) with respect to chemotherapy response, immunostaining was performed on transbronchial biopsy specimens from previously untreated patients with non-small cell lung cancer. Of the 54 patients, 34 patients (63%) and 37 patients (69%) were positive for p53 and GST-π, respectively. The response rates in the p53-positive and p53-negative group were 15 and 45%, and those in GST-π-positive and GST-π-negative groups were 16 and 47%, respectively. A multiple logistic regression analysis revealed that positive immunostaining for GST-π was a significant risk factor for clinical chemotherapy resistance. The combination of these two markers was the most important independent factor in predicting a response to chemotherapy in multiple logistic regression analysis. Immunohistochemical expression of p53 and GST-π was independently related to clinical chemoresistance in patients with non-small cell lung cancer. Combined use of these two biomarkers may be a useful predictor of clinical chemoresistance.

UR - http://www.scopus.com/inward/record.url?scp=0032703199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032703199&partnerID=8YFLogxK

U2 - 10.1159/000012068

DO - 10.1159/000012068

M3 - Article

C2 - 10575319

AN - SCOPUS:0032703199

VL - 57

SP - 318

EP - 323

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -